Mutual of America Capital Management LLC Has $13.25 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mutual of America Capital Management LLC lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,899 shares of the pharmaceutical company’s stock after selling 933 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $13,248,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Dunhill Financial LLC grew its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $33,000. Brown Lisle Cummings Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 1.1 %

Vertex Pharmaceuticals stock opened at $479.79 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market capitalization of $123.21 billion, a price-to-earnings ratio of -218.09, a PEG ratio of 2.11 and a beta of 0.41. The company’s 50 day simple moving average is $440.39 and its 200 day simple moving average is $461.10.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on VRTX shares. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and boosted their price objective for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 20th. StockNews.com cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Morgan Stanley increased their price target on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 530 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the sale, the executive vice president now owns 58,539 shares of the company’s stock, valued at $27,825,928.26. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 1,084 shares of company stock valued at $505,512. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.